Cidara Therapeutics Inc [CDTX] stock is trading at $61.53, up 7.85%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CDTX shares have gain 19.49% over the last week, with a monthly amount glided 192.72%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Citizens JMP started tracking the stock with Mkt Outperform rating on March 12, 2025, and set its price target to $46. RBC Capital Mkts started tracking the stock assigning a Outperform rating and suggested a price target of $34 on December 13, 2024. Guggenheim initiated its recommendation with a Buy and recommended $33 as its price target on November 08, 2024. H.C. Wainwright upgraded its rating to Buy for this stock on August 14, 2024, but kept the price target unchanged to $24.
Cidara Therapeutics Inc [CDTX] stock has fluctuated between $10.14 and $61.60 over the past year. Currently, Wall Street analysts expect the stock to reach $57.5 within the next 12 months. Cidara Therapeutics Inc [NASDAQ: CDTX] shares were valued at $61.53 at the most recent close of the market. An investor can expect a potential drop of -6.55% based on the average CDTX price forecast.
Analyzing the CDTX fundamentals
Cidara Therapeutics Inc [NASDAQ:CDTX] reported sales of 0.30M for the trailing twelve months, which represents a drop of -100.00%. Gross Profit Margin for this corporation currently stands at 0.81% with Operating Profit Margin at -357.44%, Pretax Profit Margin comes in at -614.55%, and Net Profit Margin reading is -598.45%. To continue investigating profitability, this company’s Return on Assets is posted at -0.94, Equity is -1.31 and Total Capital is -0.76. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 56.91 points at the first support level, and at 52.28 for the second support level. However, for the 1st resistance point, the stock is sitting at 64.16, and for the 2nd resistance point, it is at 66.78.
Ratios To Look Out For
For context, Cidara Therapeutics Inc’s Current Ratio is 3.87. In addition, the Quick Ratio stands at 3.87 and the Cash Ratio stands at 3.45. Considering the valuation of this stock, the price to sales ratio is 4536.32, the price to book ratio is 5.30.
Transactions by insiders
Recent insider trading involved RA CAPITAL MANAGEMENT, L.P., Director, that happened on Jun 26 ’25 when 2.27 million shares were purchased. Director, Mineo Chrysa completed a deal on Jun 02 ’25 to buy 2270.0 shares. Meanwhile, Director Mineo Chrysa bought 1050.0 shares on Jun 03 ’25.
